Promoter AstraZeneca Pharmaceuticals AB has confirmed that it did not create any encumbrance on its shares in AstraZeneca Pharma India Limited during the financial year 2025-26. The declaration, submitted to the stock exchanges, assures stakeholders that the shares held by the promoter remain free from any such charges or liabilities. This disclosure is significant as it provides transparency regarding the promoter's holding structure and compliance with regulatory norms.

The declaration was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any encumbrance on their holdings annually. The filing covers the period from April 1, 2025, to March 31, 2026. The document explicitly states that the promoter has not, directly or indirectly, made any encumbrance on the shares during this timeframe.

The confirmation was signed by Lars-Johan Cederbrant, Director and Authorised Signatory of AstraZeneca Pharmaceuticals AB. The letter was addressed to the Managers of Listing at both BSE Limited and National Stock Exchange of India Ltd. The promoter requested the exchanges to place the declaration on record. The filing was dated April 2, 2026, and originated from Sweden.

AstraZeneca Pharma India Limited received an order from the Deputy Commissioner of State Tax (Appeal) for FY 2018-19 involving claims of Rs 9.24 crore, impacting its financial position regarding tax liabilities. The order, passed under section 107 of the Maharashtra Goods and Services Act, 2017, upholds certain adjustments initially made by the Assistant Commissioner of State Tax Investigation. These adjustments relate to supplies made by the company under its Patient Access Program.

The order is a development in an appeal filed by the company on June 29, 2020, against the original order issued by the Assistant Commissioner of State Tax Investigation. This prior order was intimated to the stock exchanges on August 14, 2023. The company stated that the matter will be suitably challenged in due course by filing an appeal before the GST Appellate Tribunal (GSTAT).

The expected overall financial implication cannot be determined at this stage, as the matter is subject to further legal proceedings. The quantum of claims stands at Rs 9.24 crore, excluding interest and penalty. The company has not yet quantified the potential impact of interest or penalties that may arise from the order.

Details of the dispute

The following table outlines the key details of the litigation and the order received:

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Tanya Sanish, Company Secretary & Compliance Officer, signed the disclosure on behalf of AstraZeneca Pharma India Limited.